Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
57
AMRX Quote, Financials, Valuation and Earnings
Last price:
$14.61
Seasonality move
:
-12.17%
Day range:
$14.77 - $15.20
52-week range:
$6.69 - $15.42
Dividend yield:
0%
P/E ratio:
1,053.19x
P/S ratio:
1.62x
P/B ratio:
5.62x
Volume:
1.5M
Avg. volume:
3.1M
1-year change:
90.63%
Market cap:
$4.7B
Revenue:
$2.8B
EPS (TTM):
$0.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AMRX
Amneal Pharmaceuticals, Inc.
|
$807.3M | $0.18 | 6.58% | 416.62% | $15.20 |
|
APLS
Apellis Pharmaceuticals, Inc.
|
$199.3M | -$0.40 | 15.96% | -35.6% | $33.95 |
|
CORT
Corcept Therapeutics, Inc.
|
$254.9M | $0.33 | 27.74% | -71.78% | $84.00 |
|
INVA
Innoviva, Inc.
|
$102.6M | $0.43 | 6.61% | 50.34% | $33.00 |
|
NKTR
Nektar Therapeutics
|
$10.4M | -$3.29 | -3.45% | -973.8% | $123.43 |
|
PFE
Pfizer Inc.
|
$16.8B | $0.57 | 1.25% | 39.47% | $28.71 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AMRX
Amneal Pharmaceuticals, Inc.
|
$14.85 | $15.20 | $4.7B | 1,053.19x | $0.00 | 0% | 1.62x |
|
APLS
Apellis Pharmaceuticals, Inc.
|
$22.20 | $33.95 | $2.8B | 74.75x | $0.00 | 0% | 2.76x |
|
CORT
Corcept Therapeutics, Inc.
|
$39.82 | $84.00 | $4.2B | 45.50x | $0.00 | 0% | 6.42x |
|
INVA
Innoviva, Inc.
|
$23.66 | $33.00 | $1.8B | 16.97x | $0.00 | 0% | 4.65x |
|
NKTR
Nektar Therapeutics
|
$73.18 | $123.43 | $1.3B | -- | $0.00 | 0% | 75.46x |
|
PFE
Pfizer Inc.
|
$27.37 | $28.71 | $155.6B | 20.20x | $0.43 | 6.28% | 2.49x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AMRX
Amneal Pharmaceuticals, Inc.
|
104.25% | 0.556 | 83.58% | 1.31x |
|
APLS
Apellis Pharmaceuticals, Inc.
|
54.23% | 0.668 | 16.61% | 2.96x |
|
CORT
Corcept Therapeutics, Inc.
|
1% | -3.733 | 0.07% | 2.85x |
|
INVA
Innoviva, Inc.
|
20.41% | -0.061 | 18.98% | 12.93x |
|
NKTR
Nektar Therapeutics
|
66.26% | 7.810 | 16.97% | 4.07x |
|
PFE
Pfizer Inc.
|
39.94% | 0.402 | -- | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AMRX
Amneal Pharmaceuticals, Inc.
|
$274M | $72.8M | 2.24% | -587.3% | 9.28% | $96M |
|
APLS
Apellis Pharmaceuticals, Inc.
|
$433.7M | $223.2M | 6.35% | 18.94% | 48.67% | $108.3M |
|
CORT
Corcept Therapeutics, Inc.
|
$203M | $10.2M | 15.84% | 16% | 4.92% | $54.5M |
|
INVA
Innoviva, Inc.
|
$75.5M | $34.6M | 10.86% | 17.06% | 31.08% | $48.6M |
|
NKTR
Nektar Therapeutics
|
$11.6M | -$31.5M | -54.14% | -327.67% | -267.45% | -$48.9M |
|
PFE
Pfizer Inc.
|
$12.3B | $3.7B | 5.07% | 10.84% | 21.01% | $4B |
Amneal Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns AMRX or APLS?
Apellis Pharmaceuticals, Inc. has a net margin of 2.31% compared to Amneal Pharmaceuticals, Inc.'s net margin of 47.04%. Amneal Pharmaceuticals, Inc.'s return on equity of -587.3% beat Apellis Pharmaceuticals, Inc.'s return on equity of 18.94%.
Company Gross Margin Earnings Per Share Invested Capital AMRXAmneal Pharmaceuticals, Inc.34.92% $0.01 $2.6B APLSApellis Pharmaceuticals, Inc.94.58% $1.66 $876.5M -
What do Analysts Say About AMRX or APLS?
Amneal Pharmaceuticals, Inc. has a consensus price target of $15.20, signalling upside risk potential of 2.36%. On the other hand Apellis Pharmaceuticals, Inc. has an analysts' consensus of $33.95 which suggests that it could grow by 52.92%. Given that Apellis Pharmaceuticals, Inc. has higher upside potential than Amneal Pharmaceuticals, Inc., analysts believe Apellis Pharmaceuticals, Inc. is more attractive than Amneal Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMRXAmneal Pharmaceuticals, Inc.2 0 0 APLSApellis Pharmaceuticals, Inc.11 7 1 -
Is AMRX or APLS More Risky?
Amneal Pharmaceuticals, Inc. has a beta of 1.356, which suggesting that the stock is 35.638% more volatile than S&P 500. In comparison Apellis Pharmaceuticals, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.354%.
-
Which is a Better Dividend Stock AMRX or APLS?
Amneal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Apellis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Apellis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRX or APLS?
Amneal Pharmaceuticals, Inc. quarterly revenues are $784.5M, which are larger than Apellis Pharmaceuticals, Inc. quarterly revenues of $458.6M. Amneal Pharmaceuticals, Inc.'s net income of $18.1M is lower than Apellis Pharmaceuticals, Inc.'s net income of $215.7M. Notably, Amneal Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,053.19x while Apellis Pharmaceuticals, Inc.'s PE ratio is 74.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals, Inc. is 1.62x versus 2.76x for Apellis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRXAmneal Pharmaceuticals, Inc.1.62x 1,053.19x $784.5M $18.1M APLSApellis Pharmaceuticals, Inc.2.76x 74.75x $458.6M $215.7M
-
Which has Higher Returns AMRX or CORT?
Corcept Therapeutics, Inc. has a net margin of 2.31% compared to Amneal Pharmaceuticals, Inc.'s net margin of 9.32%. Amneal Pharmaceuticals, Inc.'s return on equity of -587.3% beat Corcept Therapeutics, Inc.'s return on equity of 16%.
Company Gross Margin Earnings Per Share Invested Capital AMRXAmneal Pharmaceuticals, Inc.34.92% $0.01 $2.6B CORTCorcept Therapeutics, Inc.97.79% $0.16 $638.3M -
What do Analysts Say About AMRX or CORT?
Amneal Pharmaceuticals, Inc. has a consensus price target of $15.20, signalling upside risk potential of 2.36%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $84.00 which suggests that it could grow by 110.95%. Given that Corcept Therapeutics, Inc. has higher upside potential than Amneal Pharmaceuticals, Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than Amneal Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMRXAmneal Pharmaceuticals, Inc.2 0 0 CORTCorcept Therapeutics, Inc.3 1 1 -
Is AMRX or CORT More Risky?
Amneal Pharmaceuticals, Inc. has a beta of 1.356, which suggesting that the stock is 35.638% more volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.247, suggesting its less volatile than the S&P 500 by 75.347%.
-
Which is a Better Dividend Stock AMRX or CORT?
Amneal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRX or CORT?
Amneal Pharmaceuticals, Inc. quarterly revenues are $784.5M, which are larger than Corcept Therapeutics, Inc. quarterly revenues of $207.6M. Amneal Pharmaceuticals, Inc.'s net income of $18.1M is lower than Corcept Therapeutics, Inc.'s net income of $19.4M. Notably, Amneal Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,053.19x while Corcept Therapeutics, Inc.'s PE ratio is 45.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals, Inc. is 1.62x versus 6.42x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRXAmneal Pharmaceuticals, Inc.1.62x 1,053.19x $784.5M $18.1M CORTCorcept Therapeutics, Inc.6.42x 45.50x $207.6M $19.4M
-
Which has Higher Returns AMRX or INVA?
Innoviva, Inc. has a net margin of 2.31% compared to Amneal Pharmaceuticals, Inc.'s net margin of 80.81%. Amneal Pharmaceuticals, Inc.'s return on equity of -587.3% beat Innoviva, Inc.'s return on equity of 17.06%.
Company Gross Margin Earnings Per Share Invested Capital AMRXAmneal Pharmaceuticals, Inc.34.92% $0.01 $2.6B INVAInnoviva, Inc.67.87% $1.08 $1.3B -
What do Analysts Say About AMRX or INVA?
Amneal Pharmaceuticals, Inc. has a consensus price target of $15.20, signalling upside risk potential of 2.36%. On the other hand Innoviva, Inc. has an analysts' consensus of $33.00 which suggests that it could grow by 39.48%. Given that Innoviva, Inc. has higher upside potential than Amneal Pharmaceuticals, Inc., analysts believe Innoviva, Inc. is more attractive than Amneal Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMRXAmneal Pharmaceuticals, Inc.2 0 0 INVAInnoviva, Inc.4 0 1 -
Is AMRX or INVA More Risky?
Amneal Pharmaceuticals, Inc. has a beta of 1.356, which suggesting that the stock is 35.638% more volatile than S&P 500. In comparison Innoviva, Inc. has a beta of 0.437, suggesting its less volatile than the S&P 500 by 56.321%.
-
Which is a Better Dividend Stock AMRX or INVA?
Amneal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innoviva, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Innoviva, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRX or INVA?
Amneal Pharmaceuticals, Inc. quarterly revenues are $784.5M, which are larger than Innoviva, Inc. quarterly revenues of $111.3M. Amneal Pharmaceuticals, Inc.'s net income of $18.1M is lower than Innoviva, Inc.'s net income of $89.9M. Notably, Amneal Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,053.19x while Innoviva, Inc.'s PE ratio is 16.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals, Inc. is 1.62x versus 4.65x for Innoviva, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRXAmneal Pharmaceuticals, Inc.1.62x 1,053.19x $784.5M $18.1M INVAInnoviva, Inc.4.65x 16.97x $111.3M $89.9M
-
Which has Higher Returns AMRX or NKTR?
Nektar Therapeutics has a net margin of 2.31% compared to Amneal Pharmaceuticals, Inc.'s net margin of -301.29%. Amneal Pharmaceuticals, Inc.'s return on equity of -587.3% beat Nektar Therapeutics's return on equity of -327.67%.
Company Gross Margin Earnings Per Share Invested Capital AMRXAmneal Pharmaceuticals, Inc.34.92% $0.01 $2.6B NKTRNektar Therapeutics98.34% -$1.87 $252.2M -
What do Analysts Say About AMRX or NKTR?
Amneal Pharmaceuticals, Inc. has a consensus price target of $15.20, signalling upside risk potential of 2.36%. On the other hand Nektar Therapeutics has an analysts' consensus of $123.43 which suggests that it could grow by 68.66%. Given that Nektar Therapeutics has higher upside potential than Amneal Pharmaceuticals, Inc., analysts believe Nektar Therapeutics is more attractive than Amneal Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMRXAmneal Pharmaceuticals, Inc.2 0 0 NKTRNektar Therapeutics7 0 0 -
Is AMRX or NKTR More Risky?
Amneal Pharmaceuticals, Inc. has a beta of 1.356, which suggesting that the stock is 35.638% more volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.341, suggesting its more volatile than the S&P 500 by 34.126%.
-
Which is a Better Dividend Stock AMRX or NKTR?
Amneal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRX or NKTR?
Amneal Pharmaceuticals, Inc. quarterly revenues are $784.5M, which are larger than Nektar Therapeutics quarterly revenues of $11.8M. Amneal Pharmaceuticals, Inc.'s net income of $18.1M is higher than Nektar Therapeutics's net income of -$35.5M. Notably, Amneal Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,053.19x while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals, Inc. is 1.62x versus 75.46x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRXAmneal Pharmaceuticals, Inc.1.62x 1,053.19x $784.5M $18.1M NKTRNektar Therapeutics75.46x -- $11.8M -$35.5M
-
Which has Higher Returns AMRX or PFE?
Pfizer Inc. has a net margin of 2.31% compared to Amneal Pharmaceuticals, Inc.'s net margin of -9.34%. Amneal Pharmaceuticals, Inc.'s return on equity of -587.3% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital AMRXAmneal Pharmaceuticals, Inc.34.92% $0.01 $2.6B PFEPfizer Inc.69.97% -$0.29 $154.8B -
What do Analysts Say About AMRX or PFE?
Amneal Pharmaceuticals, Inc. has a consensus price target of $15.20, signalling upside risk potential of 2.36%. On the other hand Pfizer Inc. has an analysts' consensus of $28.71 which suggests that it could grow by 4.9%. Given that Pfizer Inc. has higher upside potential than Amneal Pharmaceuticals, Inc., analysts believe Pfizer Inc. is more attractive than Amneal Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMRXAmneal Pharmaceuticals, Inc.2 0 0 PFEPfizer Inc.7 16 1 -
Is AMRX or PFE More Risky?
Amneal Pharmaceuticals, Inc. has a beta of 1.356, which suggesting that the stock is 35.638% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.751%.
-
Which is a Better Dividend Stock AMRX or PFE?
Amneal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.28% to investors and pays a quarterly dividend of $0.43 per share. Amneal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.47% of its earnings as a dividend.
-
Which has Better Financial Ratios AMRX or PFE?
Amneal Pharmaceuticals, Inc. quarterly revenues are $784.5M, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Amneal Pharmaceuticals, Inc.'s net income of $18.1M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Amneal Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,053.19x while Pfizer Inc.'s PE ratio is 20.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals, Inc. is 1.62x versus 2.49x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRXAmneal Pharmaceuticals, Inc.1.62x 1,053.19x $784.5M $18.1M PFEPfizer Inc.2.49x 20.20x $17.6B -$1.6B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
73
HYMC alert for Feb 19
Hycroft Mining Holding Corp. [HYMC] is up 3.81% over the past day.
Buy
57
GLBE alert for Feb 19
Global-e Online Ltd. [GLBE] is up 4.19% over the past day.
Sell
37
ACLS alert for Feb 19
Axcelis Technologies, Inc. [ACLS] is down 1.71% over the past day.
